✦ LIBER ✦

Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA

✍ Scribed by Ronenn Roubenoff; Richard J. Jones; Judith E. Karp; Mary Betty Stevens

Publisher: John Wiley and Sons
Year: 1987
Tongue: English
Weight: 392 KB
Volume: 30
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.1780301017

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of acute myeloid leukemia of c

Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine

✍ Dr. D. I. K. Evans; Patricia H. Morris Jones; C. J. Morley 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 2 views

Eighteen children with acute myeloid leukemia have been treated with a fourdrug protocol using cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine. The initial remission rate overall was 78%. Of 15 children who completed a week's treatment, i.e. one complete cycle, 14

Long term follow-up of patients with acu

Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen

✍ Yves Beguin; Brieuc Sautois; Patricia Forget; Jean Bury; Georges Fillet 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

In 1985, the authors published a study of acute myelogenous leuke-

The prognostic significance of leukemic

The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia

✍ Zhijian Xiao; Hua Xue; Rui Li; Li Zhang; Minghua Yu; Yushu Hao 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views